Singapore markets closed

Straits Times Index
3,287.75
-5.38(-0.16%)
S&P 500
5,071.63
+1.08(+0.02%)
Dow
38,460.92
-42.77(-0.11%)
Nasdaq
15,712.75
+16.11(+0.10%)
Bitcoin USD
63,913.43
-2,517.52(-3.79%)
CMC Crypto 200
1,360.57
-22.00(-1.59%)

CSL Limited (CMXHF)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

178.45

+2.45

(+1.39%)

At close: 03:49PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with p
PR Newswire
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Simply Wall St.
CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
CSL's (ASX:CSL) stock is up by 1.2% over the past month. We wonder if and what role the company's financials play in...